Introduction {#Sec1}
============

Rheumatoid arthritis (RA) is a chronic autoimmune disease accompanied by synovitis, cartilage erosion, and bone destruction \[[@CR1]\]. Conventional remedies, such as disease-modifying anti-rheumatic drugs (DMARDs) and non-steroidal anti-inflammatory drugs (NSAIDs), produce therapeutic effects, but serious and widespread adverse reactions to these drugs have significantly restricted their continuous use \[[@CR2]--[@CR4]\]. Herbal medicines provide an alternative choice to treat RA due to their definite efficacy with fewer side effects \[[@CR5]--[@CR7]\].

Kaempferol is a natural flavonol found in many edible plants and herbal medicines. Kaempferol shows a wide range of pharmacological activities, including anti-inflammatory and antioxidant effects \[[@CR8]--[@CR10]\]. RA is reported to be associated with oxidative stress \[[@CR11]\] and high levels of inflammatory mediators \[[@CR12]\]. Recently, studies have shown that kaempferol alleviates pathological symptoms in arthritis animal models after oral administration \[[@CR13]\]. In an in vitro study, the anti-arthritis activity of kaempferol was shown to regulate the activity of inflammatory enzymes \[[@CR14]\], the formation of osteoclasts \[[@CR15]\], and the proliferation, migration, and invasion of fibroblast-like synoviocytes \[[@CR13], [@CR16]\] at an effective concentration of 7.5--100 μM. However, our preliminary study revealed that the oral administration of kaempferol had a distinct anti-arthritis effect, while the intraperitoneal injection of kaempferol showed a marginal effect even though the intraperitoneal in vivo exposure of kaempferol was much higher than the exposure of the intragastric route. To assess this peculiarity, collagen-induced model mice were employed to evaluate the pharmacokinetics and pharmacodynamics of kaempferol. Further mechanisms were explored by analyzing the gut microbiota and small molecule metabolites based on a high-throughput transcriptomics and metabolomics.

Materials and methods {#Sec2}
=====================

Animals {#Sec3}
-------

Male DBA/1J mice (6--7 weeks) were obtained from Cavens Lab Animal Ltd. (Changzhou, Jiangsu, China). The mice were maintained in specific pathogen free conditions and fed regular chow and sterile water under a 12/12 h light--dark cycle. The experimental procedures were conducted strictly according to the guidelines of the Committee on the Care and Use of Laboratory Animals and the related ethical regulations of China Pharmaceutical University.

Collagen-induced arthritis (CIA) model mice {#Sec4}
-------------------------------------------

Bovine type II collagen (CII; Chondrex, Redmond, WA, USA) was emulsified with an equal volume of complete Freund's adjuvant (Sigma-Aldrich, St. Louis, MO, USA). DBA/1J mice were immunized via intradermal injection at the base of the tail with 100 μL of emulsion on day 0 as the first immunization. On day 21 after immunization, a booster with 100 μL of the same bovine CII emulsified in incomplete Freund's adjuvant (Chondrex, Redmond, WA, USA) was administered by the same route.

For the oral administration study, mice were gavaged daily with kaempferol (purity: 98%; MUST, Chengdu, China) at a dose of 200 mg/kg or leflunomide (purity: 98%) at a dose of 5 mg/kg from day 21 to day 48. For the alternative intraperitoneal injection study, 20 mg/kg of kaempferol was injected daily from day 21 to day 48.

Arthritis assessment {#Sec5}
--------------------

Each paw score was judged as follows: 0, no signs of arthritis; 1, mild swelling confined to the tarsal bones or ankle joint; 2, mild swelling extending from the ankle to the tarsal bones; 3, moderate swelling extending from the ankle to the metatarsal joints; and 4, severe swelling encompassing the ankle, foot, and digits or ankylosis of the limb. The scores for each paw were summed to yield a total arthritis severity score per mouse, with a maximum score of 16 for each animal.

Histopathological examination {#Sec6}
-----------------------------

On day 48, the mice were humanely euthanized, and the hind limbs were collected, immersed in 10% buffered formalin, decalcified in 10% EDTA, and embedded in paraffin. Sections (5 μm) of the joints were stained with hematoxylin and eosin (Sigma-Aldrich). All slides were evaluated by investigators blinded to the experimental conditions. The degrees of cell infiltration, synovial hyperplasia and bone erosion were scored on a scale of 0 (normal) to 4 (severe): 1, mild changes; 2, moderate changes; 3, serve changes; and 4, total destruction of the joint architecture.

Quantification of cytokines and autoantibodies {#Sec7}
----------------------------------------------

The mice were sacrificed and the serum was harvested on experimental day 48. The levels of cytokines (IL-6, IL-1β, TNF-α, IL-17, and IFN-γ; ExCell, Taichang, Jiangsu, China) and autoantibodies (anti-CII IgG; Chondrex, Redmond, WA, USA) were measured by using an enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's instructions.

Sample preparation and the pharmacokinetics of kaempferol {#Sec8}
---------------------------------------------------------

Healthy DBA/1J mice were fasted overnight; then, kaempferol was administered to the mice orally (200 mg/kg) or injected intraperitoneally (20 mg/kg). Blood samples (60 μL) were collected in heparinized tubes at 0.25, 0.5, 1, 2, 4, and 6 h, and the plasma was obtained by centrifugation at 8000 r/min for 5 min and stored at −70 °C until analysis. In an independent experiment, tissue samples were harvested at 0.25, 0.5, and 2 h, and 50 mg samples of each tissue were accurately weighed, cut into slices, added to 0.5 mL of deionized water (0.1 g/mL), and homogenized in an ice bath. Fecal samples were obtained at intervals of 0--24 h and homogenized with deionized water (1:10, w/w).

Kaempferol and kaempferol-3-*O*-glucuronide were extracted by direct precipitation \[[@CR17]\]. Briefly, 30 μL of biological sample (plasma, tissue or fecal homogenate) was added to 300 μL of acetonitrile containing IS (warfarin, 0.2 ng/mL). The mixture was shaken and centrifuged twice at 30 065*×g* for 5 min, and the supernatant was injected for analysis.

The levels of kaempferol and kaempferol-3-*O*-glucuronide in the biological samples were determined by a Shimadzu LC system with an Applied Biosystems/MDS Sciex API 5500-Qtrap triple quadrupole mass spectrometer. Chromatographic separation was achieved on a Waters XSelect HSS T3 column (3.0 mm×50 mm, 2.5 μm) at 40 °C. The mobile phase was composed of solvent A (containing 0.1% formate, v/v) and solvent B (acetonitrile), with a gradient elution (10.0%--20.0% B at 0.0--2.8 min, 20.0%--95.0% B at 2.8--5.0 min maintained for 1.5 min and 95.0%--10.0% B at 6.5--7.5 min maintained at 10% B for 2.0 min at a flow rate of 0.3 mL/min). The 3 µL samples were injected for analyses. The mass spectrometer was operated in negative ion electrospray mode. Quantification was obtained using the multiple reaction monitoring (MRM) acquisition mode by monitoring the precursor ion to product ion transitions of *m/z* 285.2 → 117.0 for kaempferol, 462.0 → 286.0 for kaempferol-3-*O*-glucuronide and 307.2 → 250.0 for IS. The data acquisition and processing was performed using Analyst 1.5.2 Software (AB SCIEX, CA, USA). The linear ranges of kaempferol and kaempferol-3-*O*-glucuronide were 0.01--30 ng/mL and 1--1000 ng/mL, respectively.

16S rRNA-assisted high-throughput sequencing analysis {#Sec9}
-----------------------------------------------------

Fecal samples from different groups were collected on day 48 and were immediately stored in liquid nitrogen. The total DNA was extracted using an E.Z.N.A. Stool DNA Kit. Then, the V3-V4 domain of the 16S rRNA gene was amplified using primers (341F: 5′-CCTAYGGGRBGCASCAG-3′; 806R: 5′-GGACTACNNGGGTATCTAAT-3′) and a Phanta Max Super-Fidelity DNA Polymerase Kit. Then, the PCR amplification product was recovered and quantified using a QuantiFluor^TM^ fluorometer. The purified amplification products were mixed in equal amounts and connected through sequencing joints. Finally, a sequencing library was constructed, and sequencing was conducted on a HiSeq 2500 instrument with PE250 sequencing.

Metabolomic analysis of the gut contents {#Sec10}
----------------------------------------

On day 48 after the first immunization, the cecal contents of the mice were recovered and freeze-dried. The samples were stored at −80 °C for further analysis. Approximately 10 mg of freeze-dried cecal contents was homogenized with 200 µL of water (1:2, w/v). The mixture was centrifuged at 10000 r/min for 10 min, and 50 μL of supernatant was transferred to a new Eppendorf tube; then, 200 μL of methanol (containing the internal standard \[^13^C~2~\]-myristic acid 5 μg/mL) was added and vortexed for 5 min and centrifuged at 20000 × *g* for 10 min at 4 °C. A 100 μL aliquot of the supernatant was dried. The following process was performed with the previously described GC-MS conditions for metabolomic analysis \[[@CR18]\]. In brief, the temperature was initially set at 100 °C for 5 min and then increased to 300 °C over 25 min. Once the temperature reached 300 °C, it was maintained for another 5 min. The masses were scanned at *m/z* 50--780. The normalized peak area (normalized by IS) was introduced in SIMCA-P software for multivariate statistical analysis.

Statistical analysis {#Sec11}
--------------------

All data are expressed as the mean ± SD. Differences among groups were evaluated by one-way ANOVA. *P*-values \< 0.05 were considered to indicate statistical significance.

Results {#Sec12}
=======

Oral administration of kaempferol alleviated arthritis in mice with CIA {#Sec13}
-----------------------------------------------------------------------

To test the therapeutic effect of kaempferol after intragastric or intraperitoneal administration, an experimental arthritis model was induced by the administration of collagen with complete Freund's adjuvant. Mice gradually lost weight after the onset of arthritis, and the spleen indices were significantly increased compared with those of the normal mice. Oral treatment with kaempferol significantly prevented the decline in body weight, and kaempferol treatment caused the mice to regain their body weight starting on day 33. The spleen index was markedly decreased after intragastric administration (Fig. [1a, b](#Fig1){ref-type="fig"}). Paw swelling was observed on day 27 after the first immunization and reached a peak on day 42. Oral kaempferol treatment significantly ameliorated the CIA symptoms in mice and reduced the arthritis index and paw thickness (Fig. [1c--e](#Fig1){ref-type="fig"}). Histopathological examination by H&E staining showed that the ankle joint in CIA mice exhibited significant pathological changes, including inflammatory cell infiltration, cell proliferation, and disorderly cell arrangement. After the intragastric administration of kaempferol, the pathological changes were significantly reduced in comparison with those of the untreated mice (Fig. [1f](#Fig1){ref-type="fig"}). The positive control leflunomide also suppressed arthritis symptoms (Fig. [1a--f](#Fig1){ref-type="fig"}). However, there was little improvement in body weight, spleen index and paw swelling after the intraperitoneal injection of kaempferol (Fig. [1a--f](#Fig1){ref-type="fig"}). In summary, oral administration, instead of the intraperitoneal injection of kaempferol, exerted a distinct effect on arthritis.Fig. 1Oral treatment with kaempferol prevents arthritis in CIA mice. **a** Changes in the body weights of the mice; **b** The spleen index was calculated as the ratio of the spleen weight to the mouse body weight; **d** Polyarthritis index; **c**, **e** Paw swelling; **f** Histological examination of ankle joint sections (H&E staining). Mean ± SD, *n* = 6. C: control, M: model, K (ig.): oral administration of kaempferol, K (ip.): intraperitoneal injection of kaempferol, L: leflunomide. ^\#\#^*P* \< 0.01 vs. C; \**P* \< 0.05, \*\**P* \< 0.01 vs. M

Kaempferol depressed inflammatory cytokine and pathogenic antibody secretion in CIA mice {#Sec14}
----------------------------------------------------------------------------------------

In comparison with those of the normal mice, the circulating levels of IL-6, TNF-α, IL-1β, and IFN-γ were much higher in arthritic mice (Fig. [2a--d](#Fig2){ref-type="fig"}). The levels of proinflammatory cytokines were significantly reduced in mice orally treated with kaempferol and leflunomide (Fig. [2a--d](#Fig2){ref-type="fig"}). However, no significant difference was observed after the parenteral administration of kaempferol in the treated group relative to the model group (Fig. [2a--d](#Fig2){ref-type="fig"}). Additionally, the total anti-CII IgG level in the plasma was markedly decreased both in mice who had been intragastrically (ig.) administered kaempferol and in leflunomide-treated mice compared to that of mice who had received an intraperitoneal (ip.) injection of kaempferol (Fig. [2e](#Fig2){ref-type="fig"}).Fig. 2Kaempferol decreases inflammatory cytokine and pathogenic antibody secretion in CIA mice. The levels of proinflammatory cytokines **a** IL-1β, **b** TNF-α, **c** IL-6, and **d** IFN-γ and **e** anti-CII antibodies. Mean ± SD, *n* = 6. C: control, M: model, K (ig.): oral administration of kaempferol, K (ip.): intraperitoneal injection of kaempferol, L: leflunomide. ^\#\#^*P* \< 0.01 vs. C; \**P* \< 0.05, \*\**P* \< 0.01 vs. M

Pharmacokinetics of kaempferol and its primary metabolite kaempferol-3-*O*-glucuronide {#Sec15}
--------------------------------------------------------------------------------------

After oral administration, kaempferol undergoes phase II glucuronidation in vivo; one of the primary metabolites identified in this process is kaempferol-3-*O*-glucuronide, which is commercially available \[[@CR17]\]. (Fig. [3a](#Fig3){ref-type="fig"}). To assess the levels of kaempferol and kaempferol-3-*O*-glucuronide in vivo, the pharmacokinetic properties were investigated via intragastric and intraperitoneal routes. In the plasma, high levels of the parent drug kaempferol and its metabolite were observed after the intraperitoneal injection of kaempferol. However, relatively low levels were observed in plasma after intragastric administration (Fig. [3b](#Fig3){ref-type="fig"}). In the spleen, the levels of kaempferol and kaempferol-3-*O*-glucuronide were relatively low after intragastric and intraperitoneal administration (Fig. [3c](#Fig3){ref-type="fig"}). Conversely, the level of kaempferol in the gut was greatly concentrated (Fig. [3d](#Fig3){ref-type="fig"}) after the oral administration of kaempferol. We hypothesized that the high level of kaempferol in the gut may be involved in the therapeutic effects of kaempferol.Fig. 3Pharmacokinetic profile of kaempferol and kaempferol-3-*O*-glucuronide after the oral administration (200 mg/kg) or intraperitoneal injection (20 mg/kg) of kaempferol. **a** The chemical structure of kaempferol and kaempferol-3-*O*-glucuronide. **b** Mean plasma concentration--time profile of kaempferol and kaempferol-3-*O*-glucuronide, *n* = 8. **c** Splenic distribution profiles of kaempferol and kaempferol-3-*O*-glucuronide, *n* = 6. **d** The concentration of kaempferol and kaempferol-3-*O*-glucuronide in feces collected in 24 h. Mean ± SD, *n* = 6. K (ig.): oral administration of kaempferol, K (ip.): intraperitoneal injection of kaempferol

Kaempferol rebalanced the dysbiosis of the gut microbiota in CIA mice {#Sec16}
---------------------------------------------------------------------

Considering the much higher level of kaempferol in the gut after oral administration, we speculated that kaempferol exerts its anti-arthritis effect by affecting the microbiota. The α-diversity of the gut microbiome in model mice did not show significant differences from that of the control mice; kaempferol treatment marginally affected the α-diversity of the gut microbiome (Fig. [4a](#Fig4){ref-type="fig"}). However, both principal coordinate analysis (PCoA) and nonmetric multidimensional scaling (NMDS) of OTUs scored by weighted UniFrac dissimilarity revealed that the microbiota of the CIA mice deviated from that of the normal control mice, with a clear separation (Fig. [4b, c](#Fig4){ref-type="fig"}). The administration of kaempferol reshaped the microbiota composition, with some of the microbiota becoming rebalanced after treatment with kaempferol (Fig. [4b--d](#Fig4){ref-type="fig"}). At the family level, 14 bacteria significantly changed in the arthritis samples compared with the control samples (*P* \< 0.05); furthermore, treatment with kaempferol regulated the levels of *Lachnospiraceae*, *Bacteroidales_S24-7_group*, *Prevotellaceae*, *Erysipelotrichaceae*, *Staphylococcaceae*, and *Alcaligenaceae* (Fig. [4e](#Fig4){ref-type="fig"}). These data indicate that oral treatment with kaempferol rebalances the intestinal gut flora in CIA mice.Fig. 4Kaempferol treatment modulates intestinal microbial composition in CIA mice. **a** α-Diversity assessed by Chao, Shannon, Simpson, and ACE indices in the control, model and kaempferol groups. **b**, **c** A plot of unconstrained principal coordinate analysis and nonmetric multidimensional scaling based on weighted UniFrac distances. **d** The microbial communities at the family level. **e** The representative microbial community was altered at the family level in the kaempferol treatment group compared with that of the CIA treatment group. Mean ± SD, *n* = 6. C: control, M: model, K (ig.): oral administration of kaempferol. ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 vs. C; \**P* \< 0.05, \*\**P* \< 0.01 vs. M

Kaempferol-mediated modulation of metabolites in CIA mouse fecal samples {#Sec17}
------------------------------------------------------------------------

The deconvolution of the metabolic features in the total ion chromatograms of fecal samples revealed 128 peaks, of which 101 metabolites were authentically identified (Fig. [5](#Fig5){ref-type="fig"}). The PLS-DA model (Fig. [6a](#Fig6){ref-type="fig"}) showed that samples from each of the three groups of samples tended to cluster closely, indicating that the metabolic features within each group were similar. Furthermore, the three groups of samples were scattered, indicating that the metabolic features of the three groups of samples were different. The OPLS analysis (Fig. [6b, c](#Fig6){ref-type="fig"}) showed a good separation and difference between the CIA mice and the normal control mice, and the CIA mice and the kaempferol-treated mice, respectively. The SUS plot highlighted the metabolites that greatly contributed to the model (Fig. [6d](#Fig6){ref-type="fig"}). In total, 44 metabolites, including organic acids, amino acids, saccharides, and lipids, were significantly different in the feces of the CIA mice compared to the normal control mice. Treatment with kaempferol reversed 54.5% (24 molecules out of the 44 metabolites, Supplementary Table [S1](#MOESM1){ref-type="media"}) of the metabolites toward the normal levels (Fig. [6e](#Fig6){ref-type="fig"}). Metabolic pathway analysis showed that these metabolites are involved in the metabolism of tryptophan, fatty acids, and secondary bile acids, and in energy production (Fig. [7](#Fig7){ref-type="fig"}). The oral administration of kaempferol regulates microbial metabolism in CIA mice.Fig. 5Typical GC/MS chromatogram of the extracted molecules in feces. Typical compounds are identified and numbered as follows: 1. Lactate; 2. Oxalic acid; 3. 2-Aminobutyric acid; 4. *L*-Norvaline; 5. *L*-Alanine; 6. Phosphoric acid; 7. *L*-Isoleucine; 8. Glycine; 9. Uracil; 10. Serine; 11. *L*-Threonine; 12. Thymine; 13. Homoserine; 14. Malic acid; 15. *L*-Aspartic acid; 16. 2-ketoglutaric acid; 17. *L*-Glutamic acid; 18. Ribose; 19. Arabinose; 20. Fucose; 21. Hypoxanthine; 22. Glucose; 23. Mannose; 24. Xanthine; 25. Myo-Inositol; 26. *L*-Tryptophan; 27. Arachidonic acid; 28. Uridine; 29. Inosine; and 30. CholesterolFig. 6Kaempferol treatment modulates the metabolites in fecal samples of CIA mice. Metabolic patterns of the three groups of mice based on the multivariate statistical analysis of the GC/MS data. **a** The score plots of the three groups and their PLS-DA models for fecal data; **b** CIA vs. normal groups and their OPLS-DA models for fecal data; **c** kaempferol treatment vs. CIA treatment and the OPLS-DA for fecal data; **d** SUS plot of fecal samples correlating the OPLS-DA models of CIA versus the control (*x*-axis) and CIA versus kaempferol treatment (*y*-axis). Accordingly, the variables in the lower left corners and higher right corners are the compounds whose levels were reversed after kaempferol treatment of CIA mice (red box). However, metabolites located along the axes were specifically altered in the model group (blue boxes) and the normal group (green boxes). **e** Heatmap visualizing the intensities of differential metabolites in the fecal samples (*n* = 6). C: control, M: model, K (ig.): oral administration of kaempferolFig. 7Typical metabolites and associated pathways modulated by kaempferol treatment

Discussion {#Sec18}
==========

Previous studies have reported that kaempferol relieves the symptoms of arthritis in mice \[[@CR13]\] and suppresses the formation of osteoclasts, and the migration and invasion of fibroblast-like synoviocytes in vitro \[[@CR13], [@CR15], [@CR16]\]. In this study, we confirmed that oral treatment with kaempferol significantly ameliorated arthritis symptoms and decreased inflammatory cytokine levels in CIA mice. Unexpectedly, the intraperitoneal injection of kaempferol showed marginal efficacy in the CIA model mice. To our surprise, intraperitoneal injection of kaempferol achieved a much higher in vivo level of kaempferol and its primary metabolite, kaempferol-3-*O*-glucuronide, than intragastric administration. In other words, despite the high levels of kaempferol-3-*O*-glucuronide and kaempferol in the circulation after intraperitoneal injection, the parenteral administration of kaempferol showed little improvement in arthritis. The distinct PK-PD discrepancy greatly challenges the underlying mechanism and the kaempferol-targeted organs and tissues.

Although the levels of kaempferol-3-*O*-glucuronide and kaempferol were relatively low in the circulating blood and spleen, we found high levels of kaempferol in the gut after oral administration. Because the gut microbiota play a crucially important role in anti-inflammatory immunity, \[[@CR19]--[@CR22]\] the gut flora were examined in the CIA model mice. The 16S rRNA sequence analysis revealed the perturbed composition of intestinal microbiota in the CIA mice, while kaempferol treatment rebalanced the intestinal microbial community. In CIA mouse fecal samples, *Lachnospiraceae* and *Staphylococcaceae* were enriched, and the abundance of *Bacteroidales_S24-7_group*, *Prevotellaceae*, *Bacteroidaceae*, *Erysipelotrichaceae*, *Alcaligenaceae*, and *Christensenellaceae* was diminished at the family level. Consistently, previous studies have suggested that *Lachnospiraceae, Staphylococcus aureus (S. aureus)*, *Prevotellaceae*, and *Bacteroidales_S24-7_group* are associated with arthritis \[[@CR23]--[@CR25]\]. It has been reported that *Bacteroidales_S24-7_group* is significantly decreased in CIA mice, \[[@CR22]\] and this bacteria are associated with the production of anti-inflammation molecules, such as acetate and propionate \[[@CR26]\]. To some extent, kaempferol reshaped the gut flora and primarily modulated the abundance of *Lachnospiraceae*, *Bacteroidales_S24-7_group*, *Prevotellaceae*, *Erysipelotrichaceae*, *Staphylococcaceae,* and *Alcaligenaceae*, suggesting that the anti-arthritis effect of kaempferol involves the intestinal microbiota.

The gut microbiota not only influence the maturation and development of the host immune system but also influence host metabolic homeostasis by cross-communication via microbial metabolites or cometabolites. In this study, a significantly perturbed metabolism was observed in the fecal extracts of CIA mice. For example, tryptophan metabolism plays an important role in microbiota-host crosstalk in health and disease \[[@CR27]\]. In the present study, reduced tryptophan and elevated indole-3-acetic acid in the CIA group demonstrated that tryptophan metabolism was enhanced in mice with arthritis. Indole-3-acetic acid, the metabolite of tryptophan in the gut, is a ligand for AhR (aryl hydrocarbon receptor), which regulates the immune response and intestinal homeostasis \[[@CR27], [@CR28]\]. Kaempferol treatment efficiently reversed the tryptophan metabolism, decreased the indole-3-acetic acid level and increased the tryptophan level, which further suggests that kaempferol modulates the gut flora.

Glucose, fructose, and the key intermediate of the citric acid cycle α-ketoglutaric acid are important factors that regulate T cell activation \[[@CR29]\] and differentiation \[[@CR30]\]. Treatment with kaempferol efficiently reduced the levels of fructose, glucose, and α-ketoglutaric acid in the gut, suggesting that kaempferol may modulate energy metabolism and affect T cell properties. In contrast to the upregulated serum fatty acid levels in CIA rats in a previous study \[[@CR31]\], the levels of many fatty acids, such as palmitoleic acid, palmitic acid, linoleic acid, and oleic acid, were significantly decreased in the feces of CIA mice. However, kaempferol reversed the decreased levels of these fatty acids, indicating the modulation of the gut flora and the turnover of intestinal lipids.

Bile acids are closely associated with immune inflammation \[[@CR32], [@CR33]\]. In addition, their metabolism and turnover exclusively involves the gut microbiota. In addition, primary bile acids are transformed into secondary bile acids by the means of the gut flora. Arthritis significantly increases the levels of cholic acid (DC) and deoxycholic acid (DOCA) and decreases the level of glycocholic acid (GCA). DOCA is a secondary bile acid predominantly metabolized by the intestinal microbiota, and a previous study reported that DOCA induces severe inflammation \[[@CR34]\]. Treatment with kaempferol decreased the DOCA level and had little effect on DC and GCA levels, again indicating that kaempferol exerts anti-arthritis effects by modulating the gut microbiota.

Conclusion {#Sec19}
==========

Intraperitoneal injection achieves high plasma levels of kaempferol and its primary metabolite, yet marginal effects are observed. Orally administered kaempferol has relatively low bioavailability and in vivo exposure, yet it shows distinct anti-arthritis activity. The high level of kaempferol in the gut after oral administration reshapes the intestinal microbial community and modulates the microbiota-mediated metabolism of tryptophan, fatty acids and secondary bile acids and energy production, which may contribute to the effectiveness of kaempferol in RA.
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